Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.

Mesa RA, Elliott MA, Schroeder G, Tefferi A

Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia.

Tefferi A, Lasho TL, Wolanskyj AP, Mesa RA

Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.

Mesa RA, Steensma DP, Hoyer J, Ketterling RP

Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment.

Koch CA, Li CY, Mesa RA, Tefferi A

Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow.

Steensma DP, Mesa RA, Reeder TL, Tefferi A, Kaufmann SH

Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: the question is "when?".

Maziarz RT, Mesa RA, Tefferi A

Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.

Mesa RA

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A, Gray LA, Reeder T, Schroeder G, Kaufmann SH

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A

The therapy of myelofibrosis: targeting pathogenesis.

Mesa RA